Home  /  Resource Library  /  Real World Long term Follow up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low Grade Follicular Lymphoma and Marginal Zone Lymphoma

Real World Long term Follow up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low Grade Follicular Lymphoma and Marginal Zone Lymphoma

Long term follow up of a study examing Yttrium-90 ibritumomab tiuxetan as first line treatment of low grade follicular and marginal zone lymphomas.